A Single-Center, Two-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of a Topical Periplaneta Americana-Derived Regenerative Solution (Meilian Fuxin Liquid) for the Treatment of Radiation Dermatitis
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Radiation, Other
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender.
• Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and require radical radiotherapy or postoperative adjuvant radiotherapy.
• Performance Status: Patients with an ECOG Performance Status score of 0 to 2.
• Consent: Patients who voluntarily agree to participate in this study and sign the informed consent form.
Locations
Other Locations
China
Sichuan University West China Hospital
RECRUITING
Chengdu
Sichuan University West China Hospital, Chengdu, Sichuan
RECRUITING
Chengdu
Contact Information
Primary
Xingchen Peng
pxx2014@163.com
+86 18980606753
Backup
Ruiwan Yuan
yuanruiwan@outlook.com
Time Frame
Start Date: 2026-03-01
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 60
Treatments
Experimental: Meilian Fuxin Solution
Topical application of Periplaneta americana-derived Meilian Fuxin Solution
Placebo_comparator: Control group
Topical application of placebo
Related Therapeutic Areas
Sponsors
Leads: West China Hospital